Clinical trials
Lung Cancer (NSCLC) clinical trials
Below are recruiting lung cancer (nsclc) clinical trials, each written for real people, not researchers. We’re tracking 1,079 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05525338RecruitingPhase 4
Test standard vs adjusted alectinib dose using blood levels
This trial compares the usual dose of alectinib with a modified dose chosen by checking alectinib blood levels. It aims to see whether adjusting the dose based on blood testing can work as well (and possibly be better tolerated) for people with ALK-positive non-small cell lung cancer.
Villejuif, Val-de-MarneAges 18 years+ - NCT06008730RecruitingPhase 2
Proton beam radiation after lung cancer surgery
This trial tests if proton beam radiation therapy is safe and effective after surgery for non-small cell lung cancer that has spread to lymph nodes in the chest. It is for people who have already had chemotherapy before their surgery.
Atlanta, GeorgiaAges 18 years+ - NCT05948865RecruitingPhase 1
Early trial drug for advanced solid tumors
This Phase 1 study tests CPO301 in adults with advanced or metastatic solid tumors that have worsened or cannot be treated with standard options. It aims to find the safest dose and understand how the treatment affects tumors, especially in certain lung cancer groups.
Los Angeles, CaliforniaAges 18 years+ - NCT06923618Recruiting
Lung Cancer and Aging in Older Adults
This trial looks at aging-related changes in older adults (70+) with early-stage lung cancer who are planning to have surgery. The goal is to better understand how these changes might affect recovery and outcomes, which could help improve care for future patients.
Créteil, Île-de-France RegionAges 70 years+ - NCT04282044RecruitingPhase 1
CRX100 drug trial for advanced cancers with or without pembrolizumab
This Phase 1 trial tests CRX100 (a new cancer medicine) alone and with pembrolizumab (an immune checkpoint drug) in people with advanced solid tumors. It’s mainly designed to check safety and side effects, and to see whether tumors respond, potentially helping people whose cancer has come back or stopped responding to standard treatment.
Scottsdale, ArizonaAges 18 years+ - NCT05492682RecruitingPhase 1
First-in-human treatment for cancer using a drug injected into tumors
This Phase 1 trial tests PeptiCRAd-1, a treatment injected into a tumor, to see how safe it is and whether it can shrink cancers. It studies people whose cancer has come back or can’t be treated with standard options.
FrankfurtAges 18 years+ - NCT07140315RecruitingPhase 1
DK222 study for lung and bladder cancer
This trial tests a new imaging drug, DK222, to see how well it works in people with non-small cell lung cancer or bladder cancer who are about to start immunotherapy. It may help doctors see if the treatment is reaching the right targets.
Baltimore, MarylandAges 18 years+ - NCT04969315RecruitingPhase 1/Phase 2
Study of two new drugs for advanced kidney, prostate, lung, or mesothelioma cancer
This study tests two new study drugs (TT-4 and TT-10) alone and together in people with certain advanced cancers that have not responded to standard treatments. The goal is to see if these drugs are safe and effective in shrinking tumors or slowing the cancer's growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06107608Recruiting
Scan for tumors in lung cancer patients on immunotherapy
This study uses a special type of PET scan to look at specific cells in non-small cell lung cancer tumors that might help doctors understand how well immunotherapy treatments are working. If you are about to start immunotherapy for advanced lung cancer, you may be able to join.
BrusselsAges 18 years+ - NCT06946927RecruitingPhase 1
Study of JMKX001899 with other drugs for advanced KRAS G12C lung cancer
This trial tests a new targeted therapy, JMKX001899, combined with other treatments for advanced non-small cell lung cancer that has a specific KRAS G12C mutation. It aims to see if this combination can help shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18–75 - NCT03958240Recruiting
Study how cancers trigger the immune system
This study looks at what makes some cancers more “noticeable” to the immune system. It may help researchers design better future immunotherapy by collecting information (often including blood samples) from people with different cancers.
ToulouseAges 18 years+ - NCT05689619Recruiting
Silibinin after one brain metastasis surgery for lung or breast cancer
This trial studies silibinin, a natural substance, to help prevent brain metastasis from coming back after surgery. It is for people with lung (NSCLC) or breast cancer who have exactly one small brain metastasis that is fully removed and has a specific lab marker in the brain tissue.
GenovaAges 18–70 - NCT05877430RecruitingPhase 1/Phase 2
Testing an anti-cancer drug plus pembrolizumab for advanced cancers
This Phase 1/2 study tests the safety and early signs of benefit from CJRB-101 when combined with pembrolizumab (Keytruda) in people with advanced or metastatic lung, head and neck, or melanoma cancer. It may help some participants, but the main goal is to see how safe the combination is and whether it can control cancer.
Irvine, CaliforniaAges 18 years+ - NCT06706076RecruitingPhase 1/Phase 2
Experimental pill for lung cancer with EGFR or HER2 changes
This study tests an experimental pill that targets cancer cells with certain gene changes (EGFR or HER2). It may help shrink tumors or slow the cancer's growth in people with advanced non-small cell lung cancer.
Phoenix, ArizonaAges 18 years+ - NCT07636785RecruitingPhase 1/Phase 2
VMD-102 Drug Study for Advanced Cancers
This study tests a new drug called VMD-102 in patients with advanced liver cancer, melanoma, kidney cancer, lung cancer, or colon cancer that hasn't responded to standard treatments. The trial will help determine if VMD-102 is safe and effective at slowing or stopping cancer growth.
Scottsdale, ArizonaAges 18–75 - NCT06983899Recruiting
Exercise to boost immunity during lung cancer immunotherapy
This trial tests whether a supervised exercise program can help improve immune activity and treatment outcomes for people with non-small cell lung cancer who are already on immunotherapy. It is designed for people who are not currently very active.
Seattle, WashingtonAges 18 years+ - NCT06956690RecruitingPhase 1/Phase 2
Testing HMBD-501 for HER3-positive advanced solid tumors
This trial tests a new drug, HMBD-501, for people with advanced solid tumors that have a specific protein called HER3. The goal is to see if the drug is safe and if it can help shrink or control the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT06950073Recruiting
Second radiation treatment for lung cancer in the chest
This study tests whether giving a second course of radiation to the chest (called retreatment) can control lung cancer that has come back or a new cancer that started there. People who have already had radiation to their chest and are healthy enough for more may be eligible.
Aarhus, JutlandAges Any age - NCT06839105RecruitingPhase 1
Testing AWT020 for advanced cancers
This study tests an experimental drug called AWT020 in people with advanced cancers that have either stopped responding to standard treatments or aren't candidates for them. The goal is to see if AWT020 is safe and tolerable across several cancer types such as lung cancer, melanoma, colorectal cancer, kidney cancer, and others.
Fuzhou, FujianAges 18 years+ - NCT06618287RecruitingPhase 1/Phase 2
Testing BMS-986507 for advanced lung and breast cancers
This study tests a new drug called BMS-986507, given in different combinations, for people with advanced solid tumors (lung cancer or breast cancer that has spread). It looks at safety, how the drug works in the body, and if it helps shrink tumors.
Birmingham, AlabamaAges 18 years+ - NCT06471296Recruiting
How viruses affect tumors and treatment response
This study looks at tumor samples from people with certain cancers to compare those caused by viruses (like HPV, HIV, or EBV) with those not caused by viruses. The goal is to understand why some tumors respond differently to treatments, which may help improve future treatment approaches.
ParisAges 18–100 - NCT06342284Recruiting
Collecting health data during radiation for lung cancer
This trial asks people getting radiation therapy for lung cancer to use a wearable device and smartphone app to track their activity and symptoms. The goal is to learn how this treatment affects patients day-to-day.
New York, New YorkAges 18 years+ - NCT05145244Recruiting
Copenhagen observational study for lung or breast cancer data
This is an observational study that collects real-world information from adults with lung cancer or breast cancer. It may help doctors better understand how people do over time and how treatments and outcomes relate to details from your medical record and tests.
CopenhagenAges 18 years+ - NCT06956001RecruitingPhase 3
Testing firmanertinib vs chemo for first-line lung cancer with specific EGFR mutations
This trial compares a new targeted therapy pill (firmanertinib) to standard chemotherapy in people with advanced non-small cell lung cancer whose tumors have a specific EGFR mutation (PACC or L861Q). If you haven't had treatment for advanced disease and your cancer matches these mutations, this study may offer a more convenient oral option.
Beijing, Beijing MunicipalityAges 18 years+
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (nsclc)?
- Yes. Clin2 currently lists 1,079 recruiting lung cancer (nsclc) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (nsclc) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (nsclc) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.